comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 00:52:56 - browse：83

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Change Healthcare cyberattack prompts Medicare loan program

explore

Wikipedia

WSS

Pharmacists can make shortage drugs, but at what cost?

NEJM study link tiny plastics in blood vessels to heart problems

How climate

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Senate committee scrutinizes Medicare Advantage brokers

HHS leader on health, climate change and biopharma emissions

focus

comprehensive

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

CDC marks new Covid

Walensky prepares to leave CDC — and Congress — behind

STAT Summit: GSK CEO on pharma giant's new direction

Hepatitis C has a cure — but many Americans still lack access to it

FDA struggles to regulate food additives, sometimes for decades

What does generative AI mean for health care? We asked experts

Lawmakers consider Medicare pay reforms for doctors

What does generative AI mean for health care? We asked experts

With psoriasis trial ahead, Alumis raises $259 million

entertainment

CEOs share strategies for surviving biotech slump

Why health workers in Gaza are injured or die at high rates

Amylyx ALS drug failure raises questions and concerns

Beam Therapeutics to lay off 20% of its staff, re

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Why health workers in Gaza are injured or die at high rates

knowledge

explore

Wikipedia

entertainment